Kolmar Korea's 6 November results announcement contained two stories. The Korean cosmetics business set another quarterly sales record. Overseas, its US, Chinese and Canadian cosmetics operations were still losing money. Both belong in an account of the company's strong third quarter.
Consolidated revenue reached KRW 828.2 billion, up 21.3% from a year earlier, while operating profit rose 40.5% to KRW 81.9 billion. Those are group figures, not a pure cosmetics-manufacturing total: the consolidated business also includes pharmaceutical company HK inno.N and packaging subsidiary Yonwoo.
The more revealing starting point for beauty is the Korean standalone operation. It shows where customer demand was becoming orders, and where those orders were becoming profit. Reading that result separately from the overseas subsidiaries makes the quarter easier to understand than a single headline about global K-beauty growth.
Q3 2026, up 34.7% year on year; separate from consolidated group revenue.
Source 1The Record Was in the Korean Order Book
Standalone sales were KRW 433.7 billion and operating profit KRW 62.9 billion. The result surpassed the previous quarter's revenue record. Newspim reported that skincare represented 48% of domestic sales and sun care another 32%. Those percentages describe the sales mix, not growth rates.
That distinction helps explain the business without exaggerating it. Two product categories accounted for four-fifths of the domestic total. The commercial task is to keep meeting demand in those categories while developing additional customers and products, rather than assume that every type of cosmetic is advancing at the same pace.
The Bottle Maker Joined the Recovery
Yonwoo also contributed. The packaging subsidiary reported KRW 83.5 billion in revenue and KRW 3 billion in operating profit, returning to profitability. The Korea Economic Daily reported that it was preparing additional staffing to run more tube-production equipment.
It is a useful reminder of how many businesses sit behind a finished skincare product. A popular formula still needs a suitable container, dependable filling and a delivery schedule. For someone following the sector, the packaging result provides a second place to look for demand, alongside the manufacturer that develops and produces the contents.
More US Sales, but Not Yet a US Profit
US revenue more than doubled to KRW 18 billion, while the operating loss narrowed to KRW 3.8 billion. China moved the other way: revenue declined to KRW 30.4 billion and its operating loss widened to KRW 4.4 billion. Canada also remained loss-making.
These are different operating situations, not contradictory headlines. A factory can gain customers and still be below the scale needed to cover its costs. Equally, a larger group can post a strong quarter while some subsidiaries go backwards. The group result should not be used to erase either outcome.
The Next Test Is Delivering the Next Orders
Management expected the Korean business's fourth-quarter year-on-year sales growth to be the strongest of 2026 and planned additional capacity for demand in the first half of 2027. Those are forward-looking statements, not completed results.
From here, the useful follow-up is quite practical: does another rise in orders come with reliable deliveries and sustained margins? For overseas operations, the question is whether increased volume continues to reduce losses. Keeping those two questions separate gives readers a clearer way to follow Kolmar than treating every new plant or customer as an immediate earnings success.
DSML research · 16 November 2026



